Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 16 studies | 28% ± 8% | |
lung | 9 studies | 22% ± 4% | |
intestine | 5 studies | 18% ± 1% | |
uterus | 4 studies | 27% ± 10% | |
liver | 4 studies | 24% ± 5% | |
kidney | 3 studies | 21% ± 4% | |
breast | 3 studies | 22% ± 4% | |
brain | 3 studies | 18% ± 3% | |
adipose | 3 studies | 19% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2507.47 | 1445 / 1445 | 100% | 38.07 | 183 / 183 |
intestine | 100% | 3150.08 | 966 / 966 | 100% | 22.40 | 527 / 527 |
stomach | 100% | 2048.20 | 359 / 359 | 100% | 27.26 | 286 / 286 |
lung | 100% | 4060.24 | 578 / 578 | 100% | 26.36 | 1154 / 1155 |
breast | 100% | 2483.63 | 459 / 459 | 100% | 32.08 | 1117 / 1118 |
prostate | 100% | 2231.54 | 245 / 245 | 100% | 20.22 | 501 / 502 |
uterus | 100% | 2520.47 | 170 / 170 | 100% | 22.70 | 458 / 459 |
thymus | 100% | 2675.59 | 653 / 653 | 100% | 23.07 | 603 / 605 |
ovary | 100% | 2422.74 | 180 / 180 | 100% | 23.17 | 428 / 430 |
bladder | 100% | 2357.71 | 21 / 21 | 99% | 20.21 | 501 / 504 |
skin | 100% | 2894.61 | 1807 / 1809 | 99% | 28.79 | 468 / 472 |
kidney | 100% | 2282.15 | 89 / 89 | 98% | 20.95 | 883 / 901 |
liver | 100% | 1458.77 | 226 / 226 | 98% | 11.69 | 397 / 406 |
pancreas | 96% | 1213.70 | 315 / 328 | 99% | 19.36 | 177 / 178 |
adrenal gland | 100% | 3494.19 | 258 / 258 | 95% | 17.63 | 219 / 230 |
brain | 79% | 899.75 | 2077 / 2642 | 100% | 23.53 | 703 / 705 |
lymph node | 0% | 0 | 0 / 0 | 100% | 29.33 | 29 / 29 |
spleen | 100% | 5053.65 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 29.02 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.96 | 1 / 1 |
adipose | 100% | 2821.20 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 6229.33 | 928 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2354.51 | 1332 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 16.35 | 79 / 80 |
heart | 93% | 1005.50 | 798 / 861 | 0% | 0 | 0 / 0 |
muscle | 33% | 227.24 | 261 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0009615 | Biological process | response to virus |
GO_0051607 | Biological process | defense response to virus |
GO_0045071 | Biological process | negative regulation of viral genome replication |
GO_0070212 | Biological process | protein poly-ADP-ribosylation |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0061014 | Biological process | positive regulation of mRNA catabolic process |
GO_0045087 | Biological process | innate immune response |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0045296 | Molecular function | cadherin binding |
GO_0070403 | Molecular function | NAD+ binding |
GO_1990404 | Molecular function | NAD+-protein ADP-ribosyltransferase activity |
GO_0003950 | Molecular function | NAD+ ADP-ribosyltransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | ZC3HAV1 |
Protein name | Zinc finger CCCH-type antiviral protein 1 (ADP-ribosyltransferase diphtheria toxin-like 13) (ARTD13) (Inactive Poly [ADP-ribose] polymerase 13) (PARP13) (Zinc finger CCCH domain-containing protein 2) (Zinc finger antiviral protein) (ZAP) Zinc finger CCCH-type containing, antiviral 1 Zinc finger CCCH-type antiviral protein 1 isoform 4 ZC3HAV1 protein |
Synonyms | ZC3HDC2 PRO1677 |
Description | FUNCTION: Antiviral protein which inhibits the replication of viruses by recruiting the cellular RNA degradation machineries to degrade the viral mRNAs. Binds to a ZAP-responsive element (ZRE) present in the target viral mRNA, recruits cellular poly(A)-specific ribonuclease PARN to remove the poly(A) tail, and the 3'-5' exoribonuclease complex exosome to degrade the RNA body from the 3'-end. It also recruits the decapping complex DCP1-DCP2 through RNA helicase p72 (DDX17) to remove the cap structure of the viral mRNA to initiate its degradation from the 5'-end. Its target viruses belong to families which include retroviridae: human immunodeficiency virus type 1 (HIV-1), moloney and murine leukemia virus (MoMLV) and xenotropic MuLV-related virus (XMRV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), togaviridae: sindbis virus (SINV) and Ross river virus (RRV). Specifically targets the multiply spliced but not unspliced or singly spliced HIV-1 mRNAs for degradation. Isoform 1 is a more potent viral inhibitor than isoform 2. Isoform 2 acts as a positive regulator of RIGI signaling resulting in activation of the downstream effector IRF3 leading to the expression of type I IFNs and IFN stimulated genes (ISGs). . |
Accessions | A0A7P0T8C6 ENST00000460845.5 ENST00000242351.10 [Q7Z2W4-1] A0A514C937 Q05DV5 Q7Z2W4 ENST00000471652.1 [Q7Z2W4-2] ENST00000680309.1 ENST00000464606.5 H7C5K1 C9J6P4 |